NCT06985953

Brief Summary

This clinical trial seeks to understand patients' experiences with the healthcare team and the quality of communication between patients and doctors in cancer clinics. The main question it aims to answer is:

  • Does TrialTalk™ improve communication between providers and patients? Participants will complete questionnaires before and after their standard of care clinic visit.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable cancer

Timeline
8mo left

Started Dec 2025

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
Dec 2025Feb 2027

First Submitted

Initial submission to the registry

May 14, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 22, 2025

Completed
6 months until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2027

Last Updated

March 25, 2026

Status Verified

September 1, 2025

Enrollment Period

1.2 years

First QC Date

May 14, 2025

Last Update Submit

March 24, 2026

Conditions

Cancer

Keywords

communication

Outcome Measures

Primary Outcomes (6)

  • Fidelity - Providers

    Fidelity to the tool by providers is measured by a 9 item qualitative questionnaire, asking how many times and how providers used TrialTalk™ when talking with their patients.

    Monthly for 6 months

  • Sustainability of TrialTalk™ communication tool

    Providers will answer a 3 item questionnaire regarding their use of TrialTalk™. Items are scored on a 5 point Likert scale, where 1 = not at all and 5 = very much. Higher scores indicate better sustainability of the tool.

    1 year

  • Change in quality of communication

    Patient participants will rate the quality of communication they receive from their provider. They will answer a 13 item questionnaire with a 6-point Likert scale, where 0= not done and 5 = excellent. Scores range from 0-65, with higher scores indicating better communication.

    Up to 2 hours

  • Change in trust of provider

    Patient participants will rate how much they trust their provider using a 6 item questionnaire. Scores are on a 5-point Likert scale, where 1 = not at all and 5 = extremely. Scores range from 6-30, with higher scores indicating greater trust.

    Up to 2 hours

  • Usefulness of tool

    Patient participants will complete a 7 item questionnaire about the visual diagram created with their provider. It is scored on a 5-point Likert scale, where 1 = not at all and 5 = extremely. Scores range from 7-35, with higher scores indicating greater usefulness.

    Up to 2 hours

  • Understanding of treatment options

    Patient participants will answer 9 yes or no questions regarding how well they understood the options presented to them during the visit.

    Up to 2 hours

Study Arms (2)

Provider participants

EXPERIMENTAL

Cancer providers who have received TrialTalk™ training.

Other: TrialTalk™

Patient participants

EXPERIMENTAL

Patients who are treated by a cancer provider who has received TrialTalk™ training.

Other: TrialTalk™

Interventions

TrialTalk™OTHER

TrialTalk™ is a communication tool that focuses on making the options visible and accessible while involving patients in the discussion.

Patient participantsProvider participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hematologists, medical oncologists, or hematology/oncology fellows
  • Willing to complete TrialTalk™ training
  • ≥ 18 years old
  • have a confirmed diagnosis of cancer
  • identify as Black, African American, or non-Hispanic White
  • potentially eligible for a therapeutic phase I, II or III clinical trial
  • can read and understand English to complete the study questionnaires
  • had previous visits with the enrolled provider

You may not qualify if:

  • providers who received previous training in the TrialTalk™ method or used it in practice before will be excluded
  • previous enrollment in cancer intervention clinical trial
  • have moderate to severe cognitive impairment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Northwestern Memorial Hospital

Chicago, Illinois, 60611, United States

NOT YET RECRUITING

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

NOT YET RECRUITING

University of Wisconsin - Madison

Madison, Wisconsin, 53705, United States

RECRUITING

MeSH Terms

Conditions

NeoplasmsCommunication

Condition Hierarchy (Ancestors)

Behavior

Study Officials

  • Monica Patel, MD

    University of Wisconsin, Madison

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Cancer Connect

CONTACT

800-622-8922clinicaltrials@cancer.wisc.edu

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2025

First Posted

May 22, 2025

Study Start

December 1, 2025

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

February 1, 2027

Last Updated

March 25, 2026

Record last verified: 2025-09

Locations

US(3)